Routledge P A, Shand D G
Clin Pharmacokinet. 1979 Mar-Apr;4(2):73-90. doi: 10.2165/00003088-197904020-00001.
Propranolol is completely absorbed after oral administration and widely distributed throughout tissues. Elimination occurs almost wholly by metabolic transformation in the liver and excretion of the resultant products in the urine. An active metabolite, 4-hydroxypropranolol and possibly other active compounds have been identified; the former only after oral administration. After intravenous administration, hepatic extraction is so efficient that drug clearance is dependent on liver blood flow. After oral administration, propranolol kinetics depend on both dose and duration of therapy, but hepatic extraction remains relatively high and leads in presystemic ('first-pass') elimination and low systemic availability. During continued administration, plasma concentrations vary quite widely due to genetic differences superimposed on which are certain constitutional factors, such as age, and environmental factors such as smoking, other drugs, and perhaps diet. Hepatic, renal, thyroid and some gastrointestinal diseases as well as hypertension, malnutrition and hypothermia may be associated with alterations in propranolol disposition, all of which are consistent with the pathophysiology of these diseases.
普萘洛尔口服后可被完全吸收,并广泛分布于全身组织。消除过程几乎完全通过肝脏中的代谢转化以及最终产物经尿液排泄来完成。已鉴定出一种活性代谢物4-羟基普萘洛尔以及可能的其他活性化合物;前者仅在口服给药后出现。静脉给药后,肝脏摄取非常有效,以至于药物清除率取决于肝血流量。口服给药后,普萘洛尔的动力学取决于剂量和治疗持续时间,但肝脏摄取仍然相对较高,导致药物在进入体循环前(“首过”)被消除,全身可用性较低。在持续给药期间,由于遗传差异叠加了某些体质因素(如年龄)以及环境因素(如吸烟、其他药物,可能还有饮食),血浆浓度变化相当大。肝脏、肾脏、甲状腺和一些胃肠道疾病以及高血压、营养不良和体温过低可能与普萘洛尔处置的改变有关,所有这些都与这些疾病的病理生理学一致。